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LIST OF ABBREVIATIONS: 
 
TRUS Transrectal ultrasound 
DRE Digital Rectal Examination 
PSA Prostate Specific Antigen 
FG Finger Guided (prostate biopsy) 
VAS Visual Analogue Score 
SEER Surveillance, Epidemiology and End Results program of the US 
National Cancer Institute 
ng/mL Nanogram per millilitre 
cc Cubic centimetres (volume) 
EAU European Association of Urology 
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PART A: PROTOCOL 
 
Title: 
 
A review of transrectal ultrasound guided prostate biopsies: is there still 
a role for finger guided prostate biopsies? 
 
Purpose of the study: 
 
To review our local experience with transrectal ultrasound guided prostate 
biopsies. A retrospective review of prostate biopsies over the last four years to 
audit our practice will be performed. We will compare diagnosis and negative 
biopsy rates, before and after the introduction of transrectal ultrasound in our 
department. In addition data on clinical, ultrasound and histopathological 
findings will be analysed. We will also be able to evaluate the disease profile 
in our population to improve our practice if needed. 
 
Background:  
 
Prostate cancer is the most common male malignancy amongst black males 
in South Africa and the second commonest amongst white males (1,2). 
Prostate biopsy, via the rectum, is an essential part of diagnosing and treating 
this disease. Traditionally needle biopsies of the prostate were performed 
blindly by digital palpation of the gland per rectum. The use of a transrectal 
ultrasound probe to guide the biopsy needle has revolutionised the procedure 
in terms of accuracy, efficiency and safety. The Department of Urology at 
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Groote Schuur Hospital acquired an ultrasound machine in 2008, enabling us 
to deliver this service to our patients. 
 
Methodology:  
 
Study design: Retrospective review 
 
Population: All patients presenting to Groote Schuur Hospital Department of 
Urology for prostate biopsies. 
 
Data collection:  Prospectively collected data via standardised proforma at 
time of biopsy, collated in database. Historical data will be extracted from 
histology reports from all prostate biopsies submitted to our institution’s 
anatomical pathology department between 2006 and 2008. This information 
will be supplemented from hospital information systems (eg. Clinicom) and 
patient folders if necessary. 
 
Data analysis: Using Microsoft Excel with statistical packages from Stata and 
PAST. 
 
Privacy and confidentiality: Data sheets are kept locked in department with 
restricted access. Computer access is restricted. Data identifying patients will 
be removed before analysis to ensure anonymity. Ethics approval will be 
obtained from the local Research and Ethics Committee of the Faculty of 
Health Sciences of the University of Cape Town. 
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Research Objectives:  
 
We expect to show improved diagnostic accuracy using the transrectal 
ultrasound guided biopsy technique compared to traditional digital guided 
biopsies. However, as our patients often present late with advanced disease, 
there may be a role for finger-guided biopsies as it is easier to diagnose 
advanced prostate cancer clinically. As a secondary research objective we will 
evaluate the role of ultrasound findings in diagnosing malignancy in our 
setting. In addition we will be able to analyse the demographic and disease 
data to evaluate our local patient profile and current management practices 
with a view to improving our service. 
 
Dissemination of results:  
 
Results will be presented at departmental and national or international level 
and will be subject to peer review.  
 
Reference: 
1. Kaestner, L-A. Is ethnicity a risk for high-grade prostate cancer? MMed 
(Urology) Thesis, University of Cape Town, 2010 
2. Heyns CF, Lecouna AJ, Trollip GS. Prostate cancer: Prevalence and 
treatment in African men. JMHG 2005; 2(4): 400-405 
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Lay Summary (for Ethics protocol) 
 
It is important for doctors to review their service and performance by way of 
regular internal quality control. This is part of clinical audit. This is especially 
important when changing one’s practice and, in addition to avoiding harm to 
patients, it often leads to an improvement in service. 
 
Prostate cancer is very common and to diagnose it, the doctor needs to take a 
sample of the prostate (biopsy), usually by using a needle and directing it with 
the help of an ultrasound machine. We have introduced this service in our 
department in 2008 and are now looking back at our results. We want to 
investigate how many prostate cancers we have diagnosed by way of prostate 
biopsies. 
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PART B: LITERATURE REVIEW 
 
INTRODUCTION 
 
Prostate cancer is the commonest malignancy amongst black males in South 
Africa and the second commonest amongst white males (1). The incidence of 
prostate cancer is increasing in the developed world but remains under 
diagnosed in the developing world where the disease often presents late (2). 
There has, however, been a dramatic decline in mortality from prostate cancer 
due to earlier detection and treatment (3). This has been largely due to 
screening with prostate-specific antigen (PSA) and an increased public health 
awareness combined with improved prostate biopsy techniques. Both these 
developments have happened relatively recently and gained widespread 
clinical acceptance in the 1990s. 
 
Biopsy of the prostate is the cornerstone of the diagnosis and treatment 
prostate cancer. The first transperineal needle aspiration of cancer cells from 
the prostate was reported by Ferguson in 1930, followed by Astraldi in 1937 
(3) with a transrectal needle biopsy. Historically, biopsies of the prostate were 
performed only when an abnormal prostate was felt on digital rectal 
examination (DRE) or if metastases were suspected. Three important 
developments significantly changed the way the prostate biopsies were 
performed. Firstly, the introduction of transrectal ultrasound enabled the 
urologist to visually guide the biopsy-needle. Secondly, the adoption of a 
systematic rather than random biopsy scheme as described by Hodge (4) in 
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the landmark paper from the Stanford group. This became necessary 
because of the increasing use of PSA in patients who had normal feeling 
prostates on DRE, necessitating a systematic sampling of the gland. Lastly, 
the use of a mechanical biopsy gun was introduced in the early 1980s, 
obtaining good quality tissue for pathological review. 
 
The urinary system was amongst the first organs evaluated by diagnostic 
ultrasound in the 1950s because of the easily recognisable echostructure of 
the kidney and the bladder. Even though transrectal ultrasonography (TRUS) 
was attempted in 1955, it took another decade before Watanabe (5) obtained 
the first sonographic picture of the prostate in 1967 using a device intended to 
visualise the heart via the oesophagus. Since then TRUS has been firmly 
established in urological practice for a variety of indications. They include 
imaging the prostate, the evaluation of azoospermia and the therapeutic 
aspiration of prostatic abscesses and cysts. However, it is the ability to 
perform real-time image guidance, most commonly for performing transrectal 
prostate biopsies, that has made the investigation so popular. Other uses 
include the placement of radioactive Iridium brachytherapy seeds, fiducial 
gold seeds used for accurate positioning in external beam radiation therapy, 
as well as probe placement for cryotherapy and high-intensity focused 
ultrasound (HIFU). The indications for prostate biopsy as well as the technical 
procedural details as described in the manuscript below, are beyond the 
scope of this literature review and the reader is referred to a standard 
contemporary textbook (6). 
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Figure 1: Examples of uses of TRUS in urological practice. Images from 
Google. (SV, seminal vesicles; PZ, peripheral zone) 
 
 
OBJECTIVES OF LITERATURE REVIEW 
 
To establish what the role of finger guided (FG) biopsies are and to 
investigate the body of evidence for FG prostate biopsy in the era where 
TRUS is the gold standard. Secondly, to review the literature on the evolution 
and current status of TRUS guided biopsies of the prostate.  
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LITERATURE SEARCH METHODOLOGY 
 
Primary searches of the English language literature were performed using the 
PubMed and Medline databases and the Google scholar search engine. Key 
words included: 
 
Manual searches of the bibliographies of relevant articles were performed. 
The guidelines of professional associations as well as standard textbooks 
were consulted. 
 
SUMMARY OF THE LITERATURE  
 
The management of prostate cancer and the role of prostate biopsies 
 
Prostate cancer comprises a heterogeneous disease spectrum and the 
management thereof depends on a variety of factors, which can be loosely 
classified into patient factors, tumour related factors and healthcare related 
factors. Table 1 shows some of the factors to be considered: 
 
Prostate biopsy, Prostate needle biopsy, Transrectal ultrasound guided, 
TRUS guided, Finger guided, Digitally guided and Digitally directed 
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Table 1: Factors affecting decision making in prostate cancer management 
Patient factors Tumour factors Healthcare facility 
Age and life expectancy Clinical stage and 
presence of metastases 
Availability of urologist 
Comorbid diseases Gleason grade Treatments offered 
Performance status Volume of disease Funding of treatment 
Patient preference PSA level and prostate 
size 
Accessibility for patient 
 
Standard treatments options offered for patients with organ-confined disease 
include (7): 
• Watchful waiting 
• Active surveillance 
• Radical prostatectomy (open, laparoscopically or robotic-assisted) 
• Brachytherapy 
• External beam radiotherapy 
• Adjuvant (early) hormonal treatment 
 
Prostate biopsies play an important part not only in the diagnosis of prostate 
cancer but also the management and treatment decisions. The stage, grade 
of cancer, volume of disease and size of the prostate (on imaging such as 
TRUS) impact directly on treatment decisions and as such the prostate biopsy 
has an important part to play. New treatment modalities such as multimodal 
treatment for high-risk disease and focal therapy also rely heavily on prostate 
biopsy findings. 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 KS Jehle – A review of transrectal ultrasound guided prostate biopsies: is there still a role for finger-guided prostate biopsies? 
University of Cape Town August 2012  16 
New evidence regarding the outcome of various treatments has shed new 
light on the long-term survival of patients. Ward et al looked at the survival of 
men with low risk prostate cancer by analysing the SEER database (8). They 
found that in men below 60 years of age, the cancer related death rate for 
patients treated with surgery were comparable to that of brachytherapy (both 
less than 1%).  For patients over the age of 60 years, the corresponding rates 
were 3.8% for surgery, 5.3% for brachytherapy and 8.4% for no treatment. 
The difference between brachytherapy and surgery was not statistically 
significant and they concluded that treatment for carcinoma of the prostate 
was preferable to no treatment, regardless of the modality used. 
 
Conversely, the results of the PIVOT trial were recently published in the New 
England Journal of Medicine (9) and suggested that some patients actually 
did better in terms of survival when they had no treatment. When followed for 
at least 12 years, patients with clinically localised prostate cancer treated with 
radical prostatectomy did not have an improved all-cause or prostate cancer 
specific survival over patients treated with observation only. The trial was 
critised for being under-powered and for lack of adhesion to the protocol as 
20% of participants in the observation group crossed over to receive surgery 
while 21% of patients randomised to receive surgery did not and were in fact 
observed for the study period. Nevertheless, the trial argues strongly towards 
observing these patients with low risk prostate cancer, with what is currently 
termed active surveillance. 
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The role of Transrectal Ultrasound in imaging the prostate 
 
Findings on TRUS include both calcifications (including corpora amylacea) 
and cystic lesions. These include those from Wolffian duct origin (ejaculatory 
duct and seminal vesicle cysts) as well as the Müllerian duct structures 
(prostatic utricle). From a prostate cancer point of view, the important 
structures to identify on TRUS are hypoechoic areas in the peripheral zone, 
which should be included in the biopsy if visualised, and extracapsular 
extension (6). Prostate cancer may be isoechoic in 39% of cases and 
hyperechoic in 1% according to Shinohara et al (10). Hypoechoic lesions 
themselves are malignant between 17% and 57% of the time and should 
therefore be included in any biopsy (11). The presence of hypoechoic lesions 
in a prostate are associated with a higher incidence of cancer per se, even if 
the specific hypoechoic area is in fact benign. Other causes of hypoechoic 
lesions include BPH nodules in the transitional zone as well as prostatitis, 
lymphoma and prostatic infarcts (6). 
 
In 2007, Toi et al (10) published a review of 7426 patients where they 
performed systematic 6 – 10 core TRUS guided biopsies on patients initially 
with added biopsies if a suspicious lesion was seen on TRUS or if it was a 
repeat biopsy (in 26%). Not only were biopsies in those patients who had a 
prostatic lesion identified on TRUS more likely to have cancer diagnosed 
(57.8% vs 30.8%), but the median percentage of the core involved with 
cancer, as well as the Gleason scores were greater indicating higher grade 
and volume cancers which were more clinically significant. This study 
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emphasised the importance of TRUS, not only in directing the biopsy needle 
to the appropriate part of the prostate, but also in identifying lesions. In their 
series, the likelihood of finding cancer increased in older men with smaller 
prostates and an abnormal DRE or PSA value above 10 ng/mL. 
 
Where to direct the biopsy needle? 
 
McNeal, after whom the zonal anatomy of the prostate is named (11), 
evaluated prostate glands removed by radical prostatectomy to establish 
where the cancers originated. In 68% the peripheral zone was thought to be 
the origin followed by the transitional zone in 24% (12). His work formed the 
basis for Hodge and Stamey’s landmark paper (4), which changed prostate 
biopsy from random sampling to a standardised systematic sextant biopsy on 
which all modern biopsy schemes are based. The zones of the prostate are 
shown in Figure 2. Hodge et al described the sextant method as follows: 
“These 6 biopsy sites were located approximately 1 cm apart and were taken 
from the apex, middle and base of the prostate bilaterally. With respect to the 
coronal plane, the biopsy sites were oriented in the center of each lobe. …. If 
a suspicious hypoechoic region was located medially or far laterally to this mid 
lobe parasagittal line of random systematic sampling additional directed 
biopsies were taken of the specific defects.” Figure 3 demonstrates the 
original Stanford method.  
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Figure 2: Normal prostate ultrasound images with diagrams indicating the 
zonal anatomy at the level of the veru montanum. A: transverse view and B: 
sagittal view. From Trabulsi et al, Campbell Walsh Urology (6) 
 
Legend: AFS - anterior fibromuscular stroma, U – urethra, TZ – transition 
zone, CZ – central zone, EJD – ejaculatory duct, PZ – peripheral zone 
 
The reasoning behind the position of the 6 cores as described is unclear and 
possibly relates to symmetry. This protocol was adhered to until Stamey 
suggested in an editorial (13) to place the needles more laterally to obtain 
better samples of the anterior horns of the peripheral zone. 
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Figure 3: The original plaster cast of a radical prostatectomy specimen used 
to illustrate the biopsy sites and direction of the needle. From Hodge et al, J 
Urol 1989 (4) 
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The number of biopsy cores 
  
The number of cores taken during prostate biopsy remains controversial. 
Whilst the aim of a biopsy is to diagnose cancer, the urologist is reluctant to 
diagnose clinically insignificant cancer and wants to minimize morbidity. The 
initial sextant biopsy as described by Hodge (4) comprised 6 cores but has 
been superseded by the modern TRUS guided biopsy schemes. See Figure 4 
for illustration.  
 
Figure 4: Various reported systematic biopsy schemes with base at the top 
and apex at bottom of picture. From Campbell Walsh Urology 10th Edition (6) 
 
A – sextant biopsy proposed by Hodge et al (1989) 
B – 10 core biopsy from Presti et al (2000) 
C – 12 core scheme 
D – 13 core or 5-region scheme after Eskew et al (1997) 
 
An early prospective randomised trial reported by Naughton et al (14) built on 
previous non-randomised findings (15,16) and suggested that 12 cores were 
better than 6 cores although this finding was on the basis of a subgroup 
analysis which showed a 21% increase in cancer detection by obtaining 
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additional lateral 6 cores. The trial was however critised as it was 
underpowered to detect a 10% or less difference in cancer between the study 
groups. Further randomised trials evaluated the number of cores by 
comparing cancer detection. Results are shown in Table 2. Of note is the 
work from Presti et al (17) where they showed that traditional sextant biopsies 
may miss up to 20% of cancers and that lesion-directed biopsies provide little 
additional cancer identification when used in addition to extended peripheral 
zone biopsies.  
 
Table 2: Trials showing increased cancer detection rates with extended 
biopsy schemes. From Campbell-Walsh Urology 10th edition (6) 
 
 
A Mexican group performed a prospective randomised trial (21) of 150 
patients comparing 12 to 18 core biopsies and found cancer in 30.7% and 
Author Number of cores Cancer detection rate 
Eskew 1997 (16) 6 
13 
26.1% 
40.3% 
Naughton 2000 (14) 6 
12 
26% 
27% 
Presti 2003 (18) 6 
8 
10 
33.5% 
39.7% 
40.2% 
Babaian et al (2000) 6 
11 
20% 
30% 
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48% respectively. The groups were well matched and there was no difference 
in the complication rates. The biopsies were however performed under 
sedation. Extended biopsy schemes using more than 18 cores, so-called 
saturation biopsies, are reserved for patients in whom a high suspicion of 
prostate cancer exists and previous biopsies have proved negative (23). In a 
study by Ashley et al (24) from the Mayo Clinic, no more abnormal pathology 
was detected when the initial biopsy involved more than 24 cores, compared 
to a standard 12 to 18-core biopsy. Scattoni et al (25) similarly reserves 
saturation biopsies (which they classify as more than 20 cores) for repeat 
biopsies where there is suspicion of cancer, but also includes active 
surveillance protocols as an indication. 
 
A review by Eichler (18) included 20698 patients in 87 studies showed that 
biopsy schemes comprising 12 cores in the standard sextant pattern with 
additional cores directed more laterally were optimal in balancing cancer yield 
versus complications. This has formed the basis for the European Association 
of Urology (EAU) guidelines (19), which state that a minimum of 8 cores 
should be sampled in small prostates (30-40cc) whilst 10 to 12 cores are 
recommended. The American Urology Association agrees with this but allows 
for additional anterior and transitional zone biopsies (20). See Figure 5. 
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Figure 5: The prostate and bladder viewed from posterior via the rectum to 
show the 5 zones for the systematic extended biopsy protocol. The 10-core 
biopsy excluded the 3 biopsies in zone 3. From Eichler et al. Diagnostic value 
of systematic biopsy methods in the investigation of prostate cancer: a 
systematic review. J Urol 2006; 175(5): 1605-1612 (19) 
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The role of finger guided prostate biopsies in an abnormal feeling 
prostate 
 
Despite the widespread acceptance of TRUS guidance as the gold standard 
in prostate biopsy and the global adoption of systematic biopsy protocols, a 
few papers have investigated the role of FG biopsies in the TRUS era. 
Current literature suggests that a palpable nodule or abnormality felt on DRE 
can be seen on TRUS and therefore more accurately biopsied than by digital 
direction only (50).  
 
Following Hodge’s 1989 publication (4), a number of papers were published 
evaluating FG biopsies. Huynh et al (37) performed TRUS and FG biopsies of 
240 palpably abnormal prostates and found an increased yield of cancer from 
47.9% to 55.4%. Furthermore, they found that 7.5% of the cancers were only 
detected in the FG biopsies and that in 27% of those patients that had 
malignancy in both FG and TRUS, the FG biopsies added more information in 
terms of the tumour volume. Van Emery et al (38) found that TRUS guidance 
was comparable to FG biopsies. On the contrary, Türkeri and his colleagues 
(39) compared FG to TRUS guided biopsies in a small group of 40 patients, 
all with a palpably abnormal prostate and found systemic TRUS guided 
biopsies to diagnose 21 cases of cancer compared to the 18 cases of FG 
biopsies, concluding that FG biopsies are unnecessary.  
 
Figueiredo et al (40) performed both FG and TRUS guided biopsies on 52 
patients at the same sitting, randomly assigning the first method. They found 
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the two techniques to be equivalent in terms of cancer detection. Resnick et al 
(41) also compared FG with TRUS guided biopsies in 45 men with an overall 
cancer yield of 31% but no difference between the two methods in patients 
with an abnormal DRE. 
 
In 2001 Garcia (42) published their experience with a group of 51 patients 
who had both TRUS guided and FG transperineal prostate biopsies at the 
same sitting, albeit with only 6 cores with each route. They concluded that 
while it was possible to perform systematic biopsies with FG via a 
transperineal route, the yield of prostate cancer was indeed related to the 
increased number of cores taken rather than the technique or approach used. 
Weaver et al (44), on the other hand, compared FG biopsies of palpable 
nodules or abnormal feeling areas with simultaneous TRUS biopsies in 51 
patients with abnormal DRE and found that 23 lesions (45.1%) were 
adenocarcinoma while the FG biopsies only diagnosed 9 cancers (17.6%). 
They concluded that TRUS is of benefit even if a nodule is felt. 
 
In the same year two urologists from Nova Scotia in Canada published a 
series of 145 patients in whom they performed 189 prostate biopsies using a 
FG systematic 8-core protocol (43). The cancer yield was 53% in men with an 
abnormal DRE (25%, 43% and 84% had PSA values below 4 ng/mL, 4-10 
ng/mL and >10 ng/mL respectively). In patients with a normal feeling prostate 
the yield was 22% and 28% for PSA values below 4 ng/mL and 4-10 ng/mL 
respectively. The authors compared their findings with the published literature 
at the time and concluded that the two techniques were equivalent in efficacy, 
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attributing the success of TRUS biopsy to the systematic nature and larger 
numbers of sampling. 
 
More recently, Chiang and colleagues (45) in Taiwan retrospectively 
compared prostate cancer detection rates in 148 patients who presented over 
a 4 year period with palpable nodules by performing both systematic 12 core 
TRUS-guided as well as 3 digitally directed FG biopsies of the nodule. They 
wanted to see if adding FG biopsy of the nodule to the standard biopsy 
protocol would increase the yield of cancer. Cancer was detected in 44.6% of 
patients with the highest detection rates from using both systematic random 
biopsies and FG biopsies together. The histology obtained from FG biopsies 
led to an increase in the Gleason grading in a number of patients but this did 
not reach statistical significance. 
 
In a study from Australia, Mancuso et al (46) also reported on 500 
consecutive patients, all with an abnormal DRE, who had both TRUS and FG 
biopsies over a 6-year period. The cancer detection rate overall was 53.6% 
with 14.6% positive on FG biopsies but negative on TRUS. In this subgroup, 
there were 38.5% who had a PSA < 4 ng/mL and 27.7% who had prostates 
larger than 50 cc. Among those patients who returned positive histology on 
both the FG and TRUS biopsies, the FG cores gave additional information on 
tumour grade and stage in 59.3% of cases, showing that in patients with an 
abnormal DRE there is a benefit in performing FG biopsies in terms of cancer 
detection and grading. 
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In summary, the literature surrounding the use of finger-guided biopsies in the 
diagnosis of prostate cancer is sparse and consists of retrospective case 
series with no prospective trials found. This is not unsurprising, as the major 
body of evidence (81% of studies) taken into account during the development 
of the 2007 AUA guidelines on prostate cancer were retrospective case 
series, with controlled clinical trials only accounting for 6% (47).  
 
Initially the trials comparing FG with TRUS guided biopsies after Hodge’s (4) 
publication consisted of small retrospective series, showing conflicting results. 
Most trials investigating FG biopsies involved only patients with abnormal 
DRE findings. Among these, there is evidence to show that FG biopsies have 
a role to play in the era of TRUS guided bio sies, especially in patients 
presenting with an abnormal DRE. However, the gold standard of TRUS 
guided systematic biopsies have been shown to be superior to targeted FG 
biopsies only. 
 
What needle to use? 
 
The advent of TRUS guided biopsies together with the spring loaded biopsy 
gun enable the urologist to use thinner needles than the older manually 
operated Tru-cut needles, but still obtain better quality cores of tissue for 
pathological review. Whilst much has been published in the literature to 
assess where prostate biopsies should be directed to effectively yet randomly 
sample the prostate, in the absence of having any imaging to guide biopsies, 
very little has been written about the length of the biopsy cores. In a recent 
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publication from Istanbul, Öbek et al (26) evaluated the hypothesis that longer 
and better quality cores will improve the sampling and thus the yield of 
prostate cancer. They found that there was a significant difference in the 
mean core length in patients with cancer and that a core length of greater 
than 11.9mm serves as a minimum to ensure quality biopsies. 
 
The importance of prostate size when looking for cancer 
 
Several authors have investigated the logical question that the size of the 
gland is inversely related to the yield of cancer because of the inherent 
problem of sampling. Karakiewics et al (27) demonstrated that, using sextant 
biopsies, the yield of cancer was 40% in glands less than 20cc, dropping 
steadily to 12% in glands sized 70cc. In a study from Canada, Al-Azab et al 
(28) found that with the benefit of TRUS in patients with PSA below 9 ng/ml, 
the strongest predictor on multivariate analysis, above PSA level and age, 
was prostate volume. When evaluating patients who have had at least one 
previous negative biopsy, Novara et al (29) demonstrated using transperineal 
saturation biopsies that size was the only predictor of a positive biopsy. His 
group from Italy reported cancer diagnoses in 47% of prostates smaller than 
40cc and only 14% in prostates larger than 60cc. A recent study from Israel 
reported similar results, stating prostates larger than 72cc should benefit from 
more than 12 cores when biopsied (30).  
 
The above findings prompted investigators to create a guide to determine the 
number of biopsies. One of these is the Vienna nomogram designed for 
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patients with a PSA value between 2 and 10 ng/mL and taking into account 
the prostate volume and age of the patient. The paper by Remzi et al (31) 
showed that biopsies using the nomogram-detected cancer in 36.7% 
compared to 22% in a historical control group using 8 biopsies. The study was 
critised for not being randomised and the groups were not comparable. In a 
prospective randomised trial, Lecuona and Heyns (32) showed that there was 
in fact no advantage in using the Vienna nomogram over an 8-core protocol. 
 
Does it matter who performs the biopsy? 
 
The literature is not uniformly clear as to what the experience or grade of the 
relevant clinicians (junior trainees vs senior trainees vs qualified specialists) 
are who perform the prostate biopsies in their studies. Whilst some clinicians 
present their personal case series, those studies from larger institutions have 
many clinicians performing the biopsies.  
 
Karam et al (33) investigated the impact of training level on the detection of 
prostate cancer on TRUS biopsy in a study of 627 patients over 3 years. The 
patients had a raised PSA between 4 and 10 ng/mL and underwent their first 
biopsy by residents in their first to fourth year of training. A senior resident 
supervised the residents for “up to five sessions” before performing the 
biopsies unsupervised. They found no difference in the cancer detection 
between the different years of residency, concluding that there was no 
learning curve associated with the TRUS biopsy of the prostate.  
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Addressing the same issue, a group from Toronto evaluated their database of 
9072 initial biopsies performed over 8 years by 4 different uroradiologists (34). 
The overall yield of cancer was 49.3% and varied between 43.8% and 52.4% 
between the operators. They concluded that there was no learning curve 
involved in the acquisition of the skill and that the volume of prostate biopsies 
performed does not impact the positive cancer detection rate.  
 
Nguyen et al (35) from Cleveland evaluated the patients’ experience of their 
biopsy by recording a Visual Analogue Score (VAS) for pain and discomfort 
during the ultrasound probe insertion, the injection of local anaesthetic and 
the taking of the biopsies. They found that the mean VAS scores were higher 
for residents, but questioned themselves whether their findings were clinically 
meaningful as the absolute differences in pain were very small.  
 
The literature therefore suggests that trainees rapidly become adept at 
performing adequate biopsies. These findings were reaffirmed in a recent 
study published in the British Journal of Urology (36) where investigators 
compared a large series of prostate biopsies performed by an experienced 
consultant urologist with those performed by a trained nurse practitioner. The 
incidence of cancer in the urologist cohort was 57.3% compared to 52.7% in 
the nurse practitioner’s cohort, leading the authors to conclude that a trained 
nurse can perform TRUS biopsies as effectively as an experienced urologist 
after an initial learning curve of 50 biopsies. 
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FURTHER RESEARCH 
 
Beyond TRUS – modern imaging techniques used with prostate biopsy 
 
Despite the significant improvements made over the last 20 years in 
diagnosing prostate cancer, the stage migration of the disease has exposed 
significant gaps in our current practice and technology. The current gold 
standard, TRUS guided systematic biopsies, does however have several 
advantages over other imaging modalities. It is safe, devoid of ionising 
radiation, relatively cheap and accessible with a short learning curve. The 
prostate is amenable to imaging, lying in close proximity to the rectum. It also 
allows real time imaging enabling clinicians to perform interventions such as 
biopsy, brachytherapy seed implantation and focal therapy. Greyscale 
ultrasound does however lack sensitivity and specificity in the detection of 
prostate cancer (50).  
 
Several new developments are being investigated to improve both the 
imaging and sampling of prostates where there is a clinical suspicion of 
malignancy. They fall beyond the scope of this literature review and are 
mentioned here for the sake of completeness, being well documented in 
several recent review articles (48,49): 
 
(i) Quantification: This method uses computer algorithms to analyse 
greyscale ultrasound data with the aim to increase cancer 
diagnosis. Systems being investigated include AUDEX, C-TRUS 
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and Histoscanning, the latter claiming sensitivity and specificity of 
90 and 72% respectively and able to diagnose lesions larger than 
0.2ml. 
(ii) Doppler: The use of both colour and power Doppler relies on the 
imaging of flow in blood vessels. This limitation of this technology is 
the low flow rate of blood in the small calibre vessels associated 
with tumour angiogenesis. 
(iii) Elastography: This technology uses the differences in the reflection 
of sound waves between different (benign and malignant) tissues. A 
further development in this field is the shear wave elastography 
(SWE) in which quantification is possible, thereby minimising the 
inter-operator variability.  
(iv) MRI-transrectal ultrasound fusion: Although 3.0 Tesla T2-weighted 
MRI has been used for some time to visualise prostate tumours, the 
cumbersome nature of the equipment, together with the 
inconsistent accuracy, has made it an unpopular choice for 
intervention. A fusion of multiparametric MRI with TRUS however is 
a more workable option and has recently shown promising results. 
(v) 3D and 4D ultrasound: although these machines allows imaging in 
two planes simultaneously in addition to computer generated 
reconstruction of the prostate gland, the increased visualisation of 
hypoechoic areas in the prostate does not negate the need for 
systematic biopsies to exclude cancers that are not characterised 
by hypoechoic areas. 
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(vi) Contrast enhanced ultrasound: Contrast enhanced ultrasound uses 
intravenous micro-bubble agents to increase Doppler signal in 
areas of high vascularity as found in tumours. 
 
Whilst many of these technologies are still in the early stages of development, 
the mere fact that they exist, heralds a new era in the search for a reliable 
way to diagnose prostate cancer. The improved imaging could, in time, lead to 
targeted biopsies and then to targeted or focal therapies. At present, however, 
the multifocal nature of prostate cancer and the limitations of greyscale 
ultrasound dictates that we persevere with extended biopsy schemes and 
focus on how we interpret biopsy findings in order to treat our patients 
appropriately. 
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ABSTRACT 
 
Objective: We compared our institution’s initial experience with transrectal 
ultrasound-guided (TRUS) prostate biopsies in a single arm prospective study 
to a historical cohort of finger guided (FG) biopsies. The primary outcome 
measure was prostate cancer detection. We documented our findings on 
TRUS including the findings of peripheral calcifications, hypoechoic lesions 
and capsular distortion and evaluated whether these had any significance in 
prostate cancer detection. 
 
Patients and Methods: All patients presenting to our institution for prostate 
biopsy were included. Indications included raised PSA and/or abnormal DRE 
or other suspicion of prostate cancer. Data on 12-core TRUS guided biopsies 
were prospectively collected and compared to a historical cohort of 6-core FG 
biopsies obtained from the pathology database of all prostate biopsies 
performed at Groote Schuur Hospital within the study period. 
 
Results: One hundred ninety two patients were included in the TRUS group 
over a 25-month period (2008 – 2010) and 262 FG biopsies were reviewed 
between 2006 and 2008. Abnormal DRE findings were present in 56.2% of 
FG and 43.3% of TRUS biopsies. Histology was available in 97.8% of cases. 
The incidence of prostate cancer was 42%. Malignant or suspicious histology 
was found in 45.6% of the FG group compared to 48.6% in the TRUS group 
(p=0.27). In patients with a normal DRE there was a trend that favoured 
TRUS for improved cancer detection, which is significant if the PSA was 
below 10 ng/mL. 
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Conclusion: Our study did not show superiority of TRUS over FG biopsies 
except when the patient had a low PSA (below 10 ng/mL) and a normal DRE. 
Systematic FG biopsies may be underutilised in the TRUS era, and may be of 
benefit in patients presenting with a PSA over 10 ng/mL or an abnormal DRE. 
This may be of value in a limited resource setting where access to TRUS is 
restricted. 
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INTRODUCTION 
 
Prostate cancer is the commonest malignancy amongst black males in South 
Africa and the second commonest amongst white males (1,2). Although the 
incidence of prostate cancer is increasing in the developed world, it remains 
under-diagnosed in the developing world where it often presents late (3). 
Biopsy of the prostate forms the cornerstone in diagnosing and treating this 
disease. Historically, needle biopsies of the prostate were performed either 
transrectally or trans-perineally, with digital palpation of the gland and 
guidance of the biopsy needle per rectum (4). Three important developments 
significantly changed the way the prostate cancer was diagnosed in the early 
1990’s. Firstly, the adoption of a systematic rather than random biopsy 
scheme as described by Hodge et al (5). Secondly, the use of a biopsy gun as 
opposed to hand-operated Tru-cut needles and thirdly, the advent of the 
transrectal ultrasound (TRUS) probe enabling the clinician to visually guide 
the biopsy needle (6).  
 
Over the last two decades, TRUS has become the gold standard in 
performing prostate biopsies (7,8). The initial work from Stanford University 
demonstrated that TRUS biopsies diagnosed cancer in 23 of 43 patients who 
had previous negative FG biopsies while confirming previously digitally 
diagnosed cancer in 94% (9). In a further publication in the same journal, they 
showed that the yield of prostate cancer was better with six systematic 
random biopsies than FG biopsies of abnormal areas in the prostate (5). The 
benefits of ultrasound in guiding biopsy needles became more apparent as 
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the understanding of prostate anatomy and distribution of carcinoma 
improved, assisted by McNeal’s description of the different zones (10).  Since 
then much work has been done to determine the optimal sites and numbers of 
prostate biopsies to maximise cancer detection of what remains a test with a 
significant sampling error. The consensus today for initial biopsies are to use 
a minimum of 10 to 12 laterally directed biopsies from the peripheral zones 
with the use of TRUS (11,12). 
 
Our institution only acquired a transrectal ultrasound probe in 2008, enabling 
us to perform TRUS guided biopsies. We prospectively collected data on all 
TRUS guided prostate biopsies since the inception of this service, using a 
standard proforma (cf Appendix 2). The aim of this review was to investigate 
our hypothesis that TRUS would increase the yield of our prostate biopsies 
which were previously performed with 6 finger-guided (FG) cores. At the same 
time we wanted to evaluate the extent to which the trainees were able to 
detect abnormalities of the prostate on TRUS by recording the findings and 
correlating them with cancer diagnoses.  
 
PATIENTS AND METHODS 
 
Approval was obtained from the Human Research Ethics Committee of the 
Faculty of Health Sciences of the University of Cape Town. (cf. Appendix 1) 
The study population included all patients undergoing prostate biopsy at our 
institution during the study period July 2006 to February 2010. The first group 
was the FG biopsy group identified from pathological records of needle 
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biopsies of the prostate performed in the time period immediately preceding 
the introduction of TRUS at our hospital. The second group was the TRUS 
guided biopsy group where data was prospectively collected since the start of 
TRUS, on a standardised proforma at the time of biopsy and combined with 
the histological findings. Only patients with complete data sets were included 
in the study. Patients who underwent FG biopsy during the TRUS period were 
excluded. 
 
Clinical parameters included patient demographics including age, reason for 
intervention  (screening or symptoms), PSA value, and clinical findings on 
DRE. DRE findings were classified from clinical stage 1 to 4 according to the 
AJCC staging system as found on initial examination by a member of our 
Urology Department (cf. Appendix 3). Absolute PSA values were recorded 
and subsequently subdivided for the purposes of analyses into 5 groups: 0-4, 
4-9.9, 10-19.9, 20-99.9 and >100 ng/mL.  
 
 TRUS was performed using a Toshiba diagnostic ultrasound machine with a 
7.5-MHz transrectal probe. Informed consent was obtained and antibiotic 
prophylaxis administered orally 30 minutes before the procedure. Local 
anaesthetic with intrarectal instillation of 20ml 2% lignocaine jelly 
(Remicaine®, AI Generics, South Africa) was used without periprostatic 
needle infiltration. The findings on TRUS were documented for both the right 
and left lobe as follows: the presence of hypoechoic areas and/or 
calcifications in the periphery and the centre of the glands as well as the 
presence of capsular distortion or the visualisation of a palpable irregularity. 
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The prostate gland was assessed in the axial plane where the transverse and 
antero-posterior measurements were taken at the point of maximum diameter, 
followed by a paramedian longitudinal measurement in the sagittal plane. The 
volume was calculated using a standard pre-programmed formula {π/6 × 
(transverse diameter) × (antero-posterior diameter) × (superior-inferior 
diameter)} based on an ellipsoid shape. The number of biopsies taken was 
documented prospectively in the TRUS group as either the routine 12 cores (2 
cores from apex, mid-zone and base of prostate on the periphery of either 
lobe) or the routine 12 cores plus additional biopsies of suspicious areas (on 
ultrasound or digital examination). Biopsies were taken using a Magnum 
Biopsy Instrument (C.R. Bard Inc, USA) with 18G 25cm Tru-cut needles. 
Cores were transferred in 2 specimen bottles for FG biopsies (left and right 
lobes) and in 6 pots for TRUS biopsies (left and right apex, mid-zone and 
base respectively). 
 
Histological diagnoses were classified for the purposes of analysis into benign 
if reported as normal prostate or benign prostatic hyperplasia or inflammation 
and as suspicious for malignancy if reported as atypical, atypical small acinar 
proliferation (ASAP) or high grade prostatic intraepithelial neoplasia (PIN). 
Gleason scores below 6 were classified as suspicious for malignancy and 6 
and higher were classified as malignant. To differentiate between negative 
biopsies and those with pathological findings, patients with suspicious findings 
were grouped together with the confirmed carcinomas.  
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Data were compiled using MicroSoft Excel® and statistical analysis was 
performed by a biostatistician on Stata® software using the Mann–Whitney U 
test for continuous variables and the Pearson’s chi-squared test for 
categorical variables. A two-tailed P-value <0.05 was accepted as significant 
with a power of 80%.  
 
RESULTS 
 
Over a 25-month period complete data sheets and pathology reports were 
collected in 192 patients who underwent TRUS guided biopsies at one 
hospital. The FG cohort comprised 262 patients over a 17-month period 
preceding the start of TRUS guided biopsies.  
 
Presenting features: Patients in the TRUS group presented mostly with 
obstructive lower urinary tract symptoms (65.2%) followed by referral with 
raised PSA (21.5%), irritative or mixed lower urinary tract symptoms (11.6%) 
and other symptoms (1.6%) such as haematuria or paralysis. 
 
Patient age, presenting PSA value and clinical findings are presented in Table 
1 together with diagnosis of biopsy. Twenty-four patients had a PSA value 
less than or equal to 4 and 399 patients a raised PSA. Between the FG and 
TRUS guided groups, the normal PSA (4 ng/mL and lower) were 12 (5%) and 
12 (6.6%) respectively with raised PSA (more than 4 ng/mL) in 229 (95%) and 
182 (93.4%) patients respectively. Statistically however, when looking at the 
whole group, both age and PSA values were significantly different.  
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Table 1: Patient age, PSA and histology 
 Finger guided 
n = 262 
TRUS guided 
n = 192 
p-value 
Age (mean ± SD) 68.4 ± 8.38 65.6 ± 7.87 p=0.0005 
PSA (median + IQR) 12 (8.8 – 52.8) 17.5 (6.5 – 24.2) p=0.0001 
DRE suspicious or 
malignant 
109/194 (56.2%) 78/180 (43.3%) p=0.013 
Benign histology 141 (54.4%) 94 (51.4%) p=0.32 
Malignant histology 118 (45.6%) 89 (48.6%) p=0.27 
Gleason 6 31.3% 41.3%  
Gleason 7 23.6% 30.7%  
Gleason 8-10 45.3% 28%  
 
Biopsies performed: Biopsies were performed by an equal number of trainees 
(6) and specialists (2) with similar level of experience in both finger guided 
and TRUS guided biopsy groups, as shown in Table 2. Trainees performed 
97.9% of the TRUS guided biopsies during the study period. 
 
Table 2: Clinicians (A-P) performing prostate biopsies with finger guidance 
(FG) and transrectal ultrasound (TRUS) guidance 
Clinician A B C D E F G H I J K L M N O P 
FG (262) 10 53 27 24 74 24 18 6 3 7 10 5 0 0 0 0 
TRUS (181) 0 0 3 0 31 15 15 3 11 4 0 30 21 13 30 5 
 
The number of biopsies taken differed in the 2 groups. In the finger guided 
group the average number of cores were 6.24 (range 2 – 12). In the TRUS 
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group all but 15 patients had 12 or more cores, taken in a systematic sextant 
fashion as described above. All but 3 patients (due to technical failure of 
biopsy gun and patient being unable to tolerate biopsy under local 
anaesthetic) who had less than 12 cores taken with TRUS guidance had 
raised PSA above 50 ng/mL, with a clinically malignant feeling prostate.  
 
Histology: Histology was available in 444 cases. The incidence of prostate 
cancer was 42% overall, followed by benign prostatic hypertrophy, prostatitis 
(mostly chronic) and atypia, ASAP and PIN. Results are shown in Figure 1. 
When comparing the FG with the TRUS group, there was no difference in the 
incidence of malignancies between the two groups. When analysing the 
results according to DRE findings, more patients with a normal feeling 
prostate in TRUS group had carcinoma (p = 0.03). Among the patients with an 
abnormal DRE and a PSA value of less than 10 ng/mL, there was statistically 
an advantage in using TRUS guided over FG biopsies. 
 
Prostatitis was diagnosed in 69 (15.2%) patients, evenly distributed between 
the 2 groups. The mean age (± SD) for patients with histological evidence of 
prostatitis was 69.4 (± 8.1) years with a mean PSA of 16.9 ng/mL (IQR 7.1 – 
19.8 ng/mL). 
 
Eighty-eight patients had a palpable nodule on rectal examination of which 
48.9% were diagnosed with malignancy. When analysing patients with an 
abnormal DRE in whom carcinoma was diagnosed, the yield using TRUS was 
significantly better only if the PSA was less the 10 ng/dL.  
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Figure 1: Histological findings in FG and TRUS guided groups 
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Figure 2: Incidence of cancer in patients presenting with a benign feeling 
prostate gland shown by PSA categories.  
 
 
Figure 3: Incidence of cancer in patients presenting with an abnormal DRE 
shown by PSA categories. 
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Features identified on TRUS of the prostate: The average size of prostates 
measured was 38.6g. The findings are presented in Table 3 below. The 
probability ratios (with a 95% confidence interval) are presented to show the 
association between TRUS findings and the incidence of malignancy on 
biopsy. Findings included hypoechoic areas, peripheral calcifications, and a 
distorted or irregular capsule with probability ratios of 1.34 (0.98-1.8), 0.9 (0.7-
1.3) and 29.0 (4.0-210.5) respectively. The findings of hypoechoic areas or 
calcifications were therefore not associated with a higher probability of finding 
malignancy in the prostate biopsy. However, when a distorted capsule is seen 
on TRUS, the probability was at least 4 times higher, and on average 29 times 
higher than the general population. In all the cases where capsular distortion 
or irregularity was seen on TRUS, the DRE was also documented as 
abnormal. 
 
Table 3: Findings on Transrectal Ultrasound with histological diagnosis 
(PZ – peripheral zone, calcif – calcification) 
TRUS findings Total Cancer No cancer 
Capsule distorted 22 (13.0%) 21 1 
Capsule intact 147 (87.0%) 50 97 
Calcification PZ 108 (60.3%) 27 81 
No calcification PZ 71 (39.7%) 21 50 
Calcification centre 36 (21.3%) 17 19 
No central calcif 133 (79.7%) 55 78 
Hypoechoic PZ 100 (54.6%) 54 46 
No hypoechoic PZ 83 (45.4%) 24 59 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 KS Jehle – A review of transrectal ultrasound guided prostate biopsies: is there still a role for finger-guided prostate biopsies? 
University of Cape Town August 2012  55 
 
Un
ive
rsi
ty 
of 
 C
ap
e T
ow
n
 KS Jehle – A review of transrectal ultrasound guided prostate biopsies: is there still a role for finger-guided prostate biopsies? 
University of Cape Town August 2012  56 
DISCUSSION 
 
Cancer detection: The yield of prostate cancer overall was 42% in our study 
population with no difference in the incidence between the FG and the TRUS 
guided groups. This is in keeping with published figures, in spite of the fact 
that there were on average double the number biopsies done in the TRUS 
group (12 cores) compared to the FG group (6 cores) (14,15). This finding 
was contrary to our expectations, as we believed TRUS not only to be 
sampling the prostate more precisely, but also obtaining double the number of 
cores.  
 
We also postulated that TRUS might be of more benefit where the DRE was 
normal but when analysing these patients, there was a trend favouring TRUS 
only if the PSA was lower than 20 ng/mL, which was statistically significant 
only when the PSA was below 10 ng/mL. The subgroup of “normal” PSA 
below 4 ng/mL did not reach significance, likely because of the small number 
of patients in this group. 
 
Digital rectal examination: The DRE was found to be abnormal in 50%. 
Among the patients who had a normal DRE, 63 were diagnosed with 
carcinoma and these patients were equally distributed between the FG and 
TRUS groups. However, when stratifying these results according to PSA 
values as shown in Figures 2 and 3, this difference in diagnosis only 
approaches statistical significance when the PSA value is less than 10 ng/mL. 
This trend is maintained whether or not the diagnoses of PIN and ASAP are 
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included in the malignant group. This finding suggests that TRUS biopsy is 
not superior to FG biopsies for patients with a PSA value of more than 10 
ng/mL, irrespective of the DRE findings. According to our data, TRUS should 
be reserved for patients with a normal DRE and a PSA value below 10 ng/mL. 
 
Of note is the finding that patients were either screened with PSA once they 
presented to the urological service with urinary symptoms or were referred 
with a raised PSA. No patient was referred with an abnormal DRE despite 
almost 50% of patients having a palpable nodule. We found that, in keeping 
with the literature, a nodule has a 49% chance of being malignant. In a 
resource limited setting the performance of DRE is cost-effective and may 
prompt earlier detection of disease and thus earlier referral for assessment. 
 
Study population: In our single arm prospective study of TRUS there were 
less biopsies performed over a 25-month period than was the case with the 
17-month retrospective control group. Two factors can account for this: 
excluded patients who underwent FG biopsies in the TRUS era, and 
secondly, the increased time needed to perform TRUS compared to FG 
biopsies. One weakness of this study is that our two study groups were found 
to be statistically different in terms of age and PSA value at presentation, 
even though our department’s clinical indication for prostate biopsy have not 
changed over the course of this study period. Although the age of patients in 
the FG biopsy group revealed a statistically significantly older population, the 
median PSA in this group was paradoxically significantly lower than in the 
TRUS guided biopsy group. This might be accounted for by the higher 
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percentage of high Gleason grade cancers (Grade 8-10) in the retrospective 
group. Whether the statistical difference in age and PSA is clinically relevant, 
is debatable. 
 
Number of biopsies: Although the current guidelines from leading professional 
bodies (7,16) suggest at least 10-core biopsies, there is evidence to suggest 
that fewer cores are adequate (17,18). The literature has however shown that 
6-core biopsies, in contrast to our findings, are inferior to 10 and 12-core 
biopsies (19-21). Although urology trainees performed both FG and TRUS 
biopsies, with equal experience in both approaches, the learning curve 
associated with TRUS biopsy might impact the quality of the TRUS biopsies in 
our study. Investigators have, however, found no learning curve associated 
with the procedure in studies that assessed the cancer detection rate (22,23). 
 
Finger guided targeted biopsies: Initially the trials comparing FG with TRUS 
guided biopsies after Hodge’s publication (5) consisted of small retrospective 
series, showing conflicting results. Most trials investigating FG biopsies 
involved only patients with abnormal DRE findings. Among these, there is 
evidence to show that FG biopsies have a role to play in the era of TRUS 
guided biopsies, especially in patients presenting with an abnormal DRE (24-
27).  
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CONCLUSION 
 
In centres where TRUS is not available, a systematic finger guided biopsy 
with a minimum of 6 cores, is a suitable alternative in patients who present 
with a raised PSA, especially if it is more than 10 ng/mL, especially if the 
patient has an abnormal feeling prostate gland on DRE. In the absence of a 
prospective randomised controlled trial directly comparing TRUS with FG 
biopsies, the role of FG biopsies remains unproven. However, the benefits of 
FG biopsies are: that it is quick, requires fewer cores and is more readily 
available than TRUS in the resource limited setting.  
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PART D: APPENDICES 
 
1. Ethics Committee letter of approval 
 
2. Data collection sheet 
 
3. Example of consent form 
 
4. AJCC prostate cancer staging 
 
5. Author Guidelines from African Journal of Urology 
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APPENDIX 1: RESEARCH ETHICS APPROVAL LETTER 
UNIVERSIlY OF CAPE TO\~IN 
, 
27 August 2010 
HREC REF~ 395/2010 
DrKJelhe 
Department of Urology 
E26 
New Groote Schuur Hospital 
Dear Dr K Jehle 
Health Sciences Faculty 
Faculty of Healtb Sciences Research Ethics Committee 
Room 852-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telepbone [021] 406 6338 • Facsimile [021J 4066411 
e-mail: sumayah.ariefdien@uctac.za 
PROJECf TITLE: REVlEW OF TRANSRE fAL ULTRASOUND GUIDED PROSTATE 
BIOPSIES AT GRcx)TE SCHUUR HOSPITAL 
Thank you for submitting your study to the Health Science Faculty Research Ethics Committee for review 
It is a pleasure to infonn you that the Ethics Committee has formally approved the above-mentioned study. 
Approval is granted for one year till the 15th September 2011. 
Please submit a progress form, using the standardised Annual Report Fonn (FHS016), if the study continues 
beyond the approval period. Please submit a Standard Closure form (FHS010)if the study is completed within 
the approval period. 
Please note that the ongoing ethical conduct of the study remains the responsibility of the principal 
investigator. 
Please quote the REC. REF in aU your correspondence. 
Yours sincerely 
PROFESSOR M BLOCKMAN rf CHAIRPERSON. "SF HUMAN ETHICS 
Federal Wide Assurance Number: ~/A00001637. 
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APPENDIX 2: DATA COLLECTION SHEET 
 
 
 
Patient Name 
____________________ 
 
Hospital no.  
_____________________ 
 
 
Date:      _____/_______/_______ 
 
Surgeon: ____________________ 
 
○Informed consent 
○Information leaflet 
○Ciprofloxacin 500mg stat 
 
OPD appt date ________ 
 
Symptoms:    
 
 
○ Obstructive  
○ Irritative 
○ Screening 
PSA Age DRE 
 
 
 
Discrete hypoechoic PZ ○ Yes ○ No ○  Left ○ Right 
Diffuse hypoechoic PZ        ○ Yes ○ No ○  Left ○ Right 
Capsule distorted PZ          ○ Yes ○ No ○  Left ○ Right 
Capsule intact                     ○ Yes ○ No ○  Left ○ Right 
Calcifications PZ                 ○ Yes ○ No ○  Left ○ Right 
Calcifications central           ○ Yes ○ No ○  Left ○ Right 
Central hypoechoic areas   ○ Yes ○ No ○  Left ○ Right 
Increased vascularity          ○ Yes ○ No ○  Left ○ Right 
 
Prostate size 
 
__________________  grams 
 
 
 
 
(Photo of ultrasound) 
 
 
 
 
 
 
 
Biopsies: ○ First  ○ Re-biopsy ○ Standard 12 core 
○ Added biopsies of abnormal areas 
 
Histology: 
 
 
○ Adeno-Ca  
○ Gleason grade ____ + _____ = 
____ 
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APPENDIX 3: EXAMPLE OF CONSENT FORM 
 
CJl 
o 
~ 
o 
CJl 
Q) 
-0 
o 
U 
PROVINCIAL ADMINISTRATION WESTERN CAPE : DEPARTMENT OF HEALTH HOS 175 
CONSENT TO MEDICAL 
PROCEDURE/EXAMINATION 
Afrikaans op keersy 
Print name te. J~l( 
NAME OF 
DOCTOR /' I Date Signature 
----
MEANS USED TO EXPLAIN ~ Via interpreter THE PROCEDURE 
NATURE OF PROCEDURE . "1 fa ItJ ftc)14/( ' 
r}?t~1~ .....  ·~.' . .. ·('} ... f.•. )]L> !0)l~ ·· .. V~, 
ANAESTHETIC: 
CONSENT TO USE OF BLOOD and/or BLOOD PRODUCTS 
Granted Withheld 
1 have explained the nature, risks and possible 
consequences of the medical procedure to the 
undersigned patient or person legally competent 
to give consent. 
CIRCLE whichever is applicable. 
Granting or withholding of consent by the un· 
dersigned patient to the use of blood and/or blood 
products should it become necessary during the 
procedure. 
CIRCLE whichever is applicable 
I agree that a sample of my blood will be taken and tested for Hepatitis B and the Human Immunodeficiency Virus should an incident of contamination ofa 
health carc worker by bodily fluids occur during he procedure. 
FULL [ ] NAME .. ..... . . 1, the undersigned, hereby consent to the OF performance of, and understand the nature, risks PATIENT and possible consequences of the above 
procedure. The doctors who perform the above 
Date 
may increase the reasonable scope thereof or 
carry out additional or alternative measures 
SIGNATURE/ (including general anaesthesia) if considered 
THUMP PRINT necessary. 
OF PATIENT 
Print name 
PERSON I Date This section to 
LEGALLY Signature be filled III if 
COMPETENT consent is given 
TO GIVE Capacity or by a person other 
CONSENT relationship to patient than the patient. 
Means by which Personally Telephonically Telegraphically 
consent was given 
Print name 
WITNESS 1 
Signature Names and signatures of witnesses to the 
signing of this document by the patient or a 
person legally competent to give consent on 
Print name behalf of the patient. 
WITNESS 2 
Signature 
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APPENDIX 4: AJCC STAGING OF PROSTATE CANCER 
 
 
Figure A, T4 tumor invading adjacent structures other 
than seminal vesicles, such as bladder, rectum, levator 
muscles, and/or pelvic wall. 
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provided by the American Cancer Society 
0 ' 0 
PSA I Gleason 
PSA<10 Gleason ,;6 
PSA<10 Gleason ,;6 
PSAX Gleason X 
PSA <20 Gleason 7 
PSA 2:10<20 Gleason ,;6 
PSA 2:10<20 Gleason ,;6 
PSA <20 Gleason 7 
PSA <20 Gleason ,;7 
PSAX Gleason X 
Any PSA Any Gleason 
PSA 2:20 Any Gleason 
Any PSA Gleason 2:8 
Any PSA Any Gleason 
Any PSA Any Gleason 
Any PSA Any Gleason 
Any PSA Any Gleason 
• ® 
alcc 
Definitions 
.................................... . ................................... 
Primary Tumor (T) Pathologic (pT)' 
CLINICAL p12 Organ confined 
TX 
TO 
Tl 
Tla 
Tlb 
Tlc 
12 
12a 
12b 
12c 
13 
13a 
13b 
T4 
Primary tumor cannot be assessed p12a Unilateral, one-half of 
No evidence of primary tumor one side or less 
Clinically inapparent tumor neither p12b Unilateral, involving more than 
palpable nor visible by imaging one-half of side but not both sides 
Tumor incidental histologic finding p12c Bilateral disease 
in 5% or less of tissue resected p13 Extraprostatic extension 
Tumor incidental histologic finding p13a Extraprostatic extension 
in more than 5% of tissue resected or microscopic invasion 
Tumor identified by needle of bladder necl(1 
biopsy (for example, because p13b Seminal vesicle invasion 
of elevated PSA) pT4 I nvasion of rectum, levator 
Tumor confined within prostate' muscles, and/or pelvic wall 
Tumor involves one-half .................................... 
of one lobe or less Regional Lymph Nodes (N) 
Tumor involves more than one-half CLINICAL 
of one lobe but not both lobes NX Regional lymph nodes 
Tumor involves both lobes were not assessed 
Tumor extends through NO No regional lymph node metastasis 
the prostate capsule2 Nl Metastasis in regional 
Extracapsular extension lymph node(s) 
(unilateral or bilateral) PATHOLOGIC 
Tumor invades seminal vesicle(s) pNX Regional nodes not sampled 
Tumor is fixed or invades adjacent pNO No positive regional nodes 
structures other than seminal pNl Metastases in regional node(s) 
vesicles, such as external sphincter, 
.................................... 
rectum, bladder, levator muscles, Distant Metastasis (M), 
and/or pelvic wall (Figure A) 
MO No distant metastasis 
Ml Distant metastasis 
Mla Nonregionallymph node(s) 
Mlb Bone(s) 
Mlc Other site(s) with or 
without bone disease 
.......................................................................... 
Notes 
, Tumorlound in one or both lobes by needle biopsy, but not palpable or reliably visible by imaging, is classified as T1c. 
2 Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is classified not as Tl but as n. 
3 There is no pathologicTl classification. 
4 Positive surgical margin should be indicated byan Rl 
descriptor (residual microscopic disease). 
5 When more than one site 01 metastasis is present, the 
most advanced category is used. pM1c is most advanced. 
6 When either PSA or Gleason is not available, grouping should be determined 
by T stage and/or either PSA or Gleason as available. 
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APPENDIX 5: AUTHOR GUIDELINES FOR AFRICAN JOURNAL OF 
UROLOGY 
 
The African Journal of Urology welcomes original papers, case reports and 
letters to the editor from any country of the world, particularly from Africa.  
 
Format: Articles are accepted in English or French language. They should be 
carefully reviewed for accuracy of typing, spelling and grammar before they 
are submitted, since these mistakes might delay the acceptance of the article. 
They should be written in double spacing. The computer program used should 
be MS Word, and the articles should be sent as Word documents. Authors 
should retain a copy of the article for references. 
 
Organization: Original articles on clinical and scientific aspects of urology and 
its associated specialities should be organized as follows: 
The title page should give the following information: (a) title of article (b) 
names and initials of authors (c) institution to which the work should be 
attributed. (d) 1 - 5 key words should be typed at the bottom of the page (e) 
name and full postal address, telephone, fax number and Email address of 
the author to whom the reviewers‘ comments and requests for reprints should 
be sent (f) running title. The title should be concise and clear and should not 
contain abbreviations. 
 
The abstract should consist of a brief summary of the article and should be 
subdivided into objective, patients/material and methods, results, conclusion. 
The abstract should be self-explanatory, without reference to the text. 
Abbreviations may be included, provided they are defined in the abstract as 
well as in the main text. 
 
The introduction should be short and include both a brief review of the data in 
the literature, which are strictly related to the subject and express the exact 
aim of the work. 
 
Material/Patients and Methods: The patients' characteristics and the 
technique(s) applied should be described in detail. The statistical analysis 
method should be exactly defined and its reference should be mentioned. 
 
Results: The results of the work should be presented in detail. The number of 
patients should be followed by the percentage. Results that are presented in 
tables should not be repeated in the Results section. 
 
The Discussion should be limited to the reported findings and their 
implications.  
 
References: References should conform to the Vancouver style and should 
be numbered consecutively in the order in which they appear (and not listed 
alphabetically). They should be indicated by Arabic numerals in parentheses. 
Only the first six authors should be listed. If there are more 
than six then the first six should be listed followed by et al. Note that journal 
titles are abbreviated in accordance with Index Medicus. 
